ProNet Alfa

Primær information

  • Handelsnavn:
  • ProNet Alfa Flydende middel
  • Lægemiddelform:
  • Flydende middel
  • Sammensætning:
  • 1000 g/l sprede-klæbemiddel
  • Brugt til:
  • Planter
  • Medicin typen:
  • agrokemiske

Dokumenter

  • for den brede offentlighed:
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.


    Anmode informationsbrochure for offentligheden.

  • for sundhedspersonale:
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.


    Anmode informationsbrochure for sundhedspersonale.

Lokation

  • Fås i:
  • ProNet Alfa Flydende middel
    Danmark
  • Sprog:
  • dansk

Andre oplysninger

Status

  • Kilde:
  • SEGES Landbrug & Fødevarer
  • Autorisation status:
  • Markedsført
  • Sidste ændring:
  • 08-02-2018
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.

    Anmode informationsbrochure for offentligheden.

20-2-2018

Opinion/decision on a Paediatric investigation plan (PIP):    -, Andexanet alfa, Therapeutic area: Other

Opinion/decision on a Paediatric investigation plan (PIP): -, Andexanet alfa, Therapeutic area: Other

Europe - EFSA - European Food Safety Authority EFSA Journal

26-1-2018

Pending EC decision:  Lamzede, velmanase alfa, Opinion date: 25-Jan-2018

Pending EC decision: Lamzede, velmanase alfa, Opinion date: 25-Jan-2018

Europe - EMA - European Medicines Agency

23-1-2018

Orphan designation:  Pegunigalsidase alfa,  for the: Treatment of Fabry disease

Orphan designation: Pegunigalsidase alfa, for the: Treatment of Fabry disease

Europe - EMA - European Medicines Agency

27-3-2018

Lamzede (Chiesi Farmaceutici S.p.A.)

Lamzede (Chiesi Farmaceutici S.p.A.)

Lamzede (Active substance: velmanase alfa) - Centralised - Authorisation - Commission Decision (2018)1964 of Tue, 27 Mar 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3922

Europe -DG Health and Food Safety

23-3-2018

EU/3/18/1992 (argenx BVBA)

EU/3/18/1992 (argenx BVBA)

EU/3/18/1992 (Active substance: Efgartigimod alfa) - Orphan designation - Commission Decision (2018)1881 of Fri, 23 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/245/17

Europe -DG Health and Food Safety

23-3-2018

Withdrawn application:  Aranesp, darbepoetin alfa, Post-authorisation

Withdrawn application: Aranesp, darbepoetin alfa, Post-authorisation

Europe - EMA - European Medicines Agency

21-3-2018

EU/3/16/1763 (Quintiles Ireland Limited)

EU/3/16/1763 (Quintiles Ireland Limited)

EU/3/16/1763 (Active substance: Tadekinig alfa) - Transfer of orphan designation - Commission Decision (2018)1825 of Wed, 21 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/150/16/T/01

Europe -DG Health and Food Safety

19-3-2018

Pegasys (Roche Registration GmbH)

Pegasys (Roche Registration GmbH)

Pegasys (Active substance: peginterferon alfa-2a) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)1692 of Mon, 19 Mar 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/395/T/100

Europe -DG Health and Food Safety

5-3-2018

IDELVION (CSL Behring GmbH)

IDELVION (CSL Behring GmbH)

IDELVION (Active substance: albutrepenonacog alfa) - Centralised - Yearly update - Commission Decision (2018)1417 of Mon, 05 Mar 2018

Europe -DG Health and Food Safety

5-3-2018

GONAL-f (Merck Serono Europe Limited)

GONAL-f (Merck Serono Europe Limited)

GONAL-f (Active substance: Follitropin alfa) - Centralised - Yearly update - Commission Decision (2018)1411 of Mon, 05 Mar 2018

Europe -DG Health and Food Safety

21-2-2018

PegIntron (Merck Sharp and Dohme Limited)

PegIntron (Merck Sharp and Dohme Limited)

PegIntron (Active substance: Peginterferon alfa-2b) - Centralised - Yearly update - Commission Decision (2018)1125 of Wed, 21 Feb 2018

Europe -DG Health and Food Safety

21-2-2018

ViraferonPeg (Merck Sharp and Dohme Limited)

ViraferonPeg (Merck Sharp and Dohme Limited)

ViraferonPeg (Active substance: Peginterferon alfa-2b) - Centralised - Yearly update - Commission Decision (2018)1124 of Wed, 21 Feb 2018

Europe -DG Health and Food Safety

9-2-2018

STRENSIQ (Asfotase Alfa) Solution [Alexion Pharmaceuticals Inc.]

STRENSIQ (Asfotase Alfa) Solution [Alexion Pharmaceuticals Inc.]

Updated Date: Feb 9, 2018 EST

US - DailyMed

17-1-2018

Ribavirin

Ribavirin

Ribavirin is an antiviral medication used together with an interferon alfa product (such as Peg-Intro or Intron A) to treat chronic hepatitis C. Ribavirin is available under the following different brand names: Rebetol, Ribasphere, RibaPak, Copegus, Virazole, and Moderiba.

US - RxList

10-1-2018

ADYNOVI (Baxalta Innovations GmbH)

ADYNOVI (Baxalta Innovations GmbH)

ADYNOVI (Active substance: rurioctocog alfa pegol) - Centralised - Authorisation - Commission Decision (2018)116 of Wed, 10 Jan 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4195

Europe -DG Health and Food Safety

14-12-2017

EU/3/17/1953 (Protalix B.V)

EU/3/17/1953 (Protalix B.V)

EU/3/17/1953 (Active substance: Pegunigalsidase alfa) - Orphan designation - Commission Decision (2017)8785 of Thu, 14 Dec 2017 European Medicines Agency (EMA) procedure number: EMA/OD/138/17

Europe -DG Health and Food Safety

13-12-2017

Strensiq (Alexion Europe SAS)

Strensiq (Alexion Europe SAS)

Strensiq (Active substance: asfotase alfa) - Centralised - Yearly update - Commission Decision (2017)8704 of Wed, 13 Dec 2017

Europe -DG Health and Food Safety

8-12-2017

ALFERON (Interferon Alfa-N3) Injection [Hemispherx Biopharma, Inc]

ALFERON (Interferon Alfa-N3) Injection [Hemispherx Biopharma, Inc]

Updated Date: Dec 8, 2017 EST

US - DailyMed

8-12-2017

BRINEURA (Cerliponase Alfa) Kit [BioMarin Pharmaceutical Inc.]

BRINEURA (Cerliponase Alfa) Kit [BioMarin Pharmaceutical Inc.]

Updated Date: Dec 8, 2017 EST

US - DailyMed

28-11-2017

Advate (Baxter AG)

Advate (Baxter AG)

Advate (Active substance: octocog alfa) - Referral - Commission Decision (2017)7981 of Tue, 28 Nov 2017 European Medicines Agency (EMA) procedure number: EMEA/H/C/520/A-31

Europe -DG Health and Food Safety

28-11-2017

Nuwiq (Octapharma AB)

Nuwiq (Octapharma AB)

Nuwiq (Active substance: simoctocog alfa) - Referral - Commission Decision (2017)7982 of Tue, 28 Nov 2017 European Medicines Agency (EMA) procedure number: EMEA/H/C/2813/A31/15

Europe -DG Health and Food Safety

28-11-2017

MEPSEVII (Vestronidase Alfa) Injection [Ultragenyx Pharmaceutical Inc.]

MEPSEVII (Vestronidase Alfa) Injection [Ultragenyx Pharmaceutical Inc.]

Updated Date: Nov 28, 2017 EST

US - DailyMed

20-11-2017

KOGENATE Bayer (Bayer AG)

KOGENATE Bayer (Bayer AG)

KOGENATE Bayer (Active substance: Recombinant coagulation factor VIII (octocog alfa)) - Referral - Commission Decision (2017)7811 of Mon, 20 Nov 2017 European Medicines Agency (EMA) procedure number: EMEA/H/C/275/A31/185

Europe -DG Health and Food Safety

20-11-2017

Helixate NexGen (Bayer AG)

Helixate NexGen (Bayer AG)

Helixate NexGen (Active substance: Recombinant coagulation factor VIII (octocog alfa)) - Referral - Commission Decision (2017)7812 of Mon, 20 Nov 2017 European Medicines Agency (EMA) procedure number: EMEA/H/C/276/A31/178

Europe -DG Health and Food Safety

20-11-2017

ATryn (Laboratoire franCais du Fractionnement et des Biotechnologies)

ATryn (Laboratoire franCais du Fractionnement et des Biotechnologies)

ATryn (Active substance: antithrombin alfa) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2017)7806 of Mon, 20 Nov 2017 European Medicines Agency (EMA) procedure number: EMEA/H/C/587/T/31

Europe -DG Health and Food Safety

17-11-2017

NovoEight (Novo Nordisk A/S)

NovoEight (Novo Nordisk A/S)

NovoEight (Active substance: turoctocog alfa) - Referral - Commission Decision (2017)7770 of Fri, 17 Nov 2017 European Medicines Agency (EMA) procedure number: EMEA/H/C/2719/A31/14

Europe -DG Health and Food Safety